共 213 条
[1]
Fanouriakis A(2019)2019 update of the EULAR recommendations for the management of systemic lupus erythematosus Ann Rheum Dis 78 736-745
[2]
Kostopoulou M(2021)Disease severity, flares and treatment patterns in adults with systemic lupus erythematosus in the UK: a real-world observational retrospective cohort analysis Rheumatol Adv Pract 5 rkab061-283
[3]
Alunno A(2020)Patient-reported lupus flare symptoms are associated with worsened patient outcomes and increased economic burden J Manag Care Spec Pharm 26 275-18
[4]
Aringer M(2021)Frequency, severity and costs of flares increase with disease severity in newly diagnosed systemic lupus erythematosus: a real-world cohort study, United States, 2004–2015 Lupus Sci Med 8 14-28
[5]
Bajema I(2018)The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults: executive summary Rheumatology (Oxford) 57 20-333
[6]
Boletis JN(2010)Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review Ann Rheum Dis 69 327-1808
[7]
Langham J(2015)Effect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus-the Hopkins Lupus Cohort Lupus Sci Med 2 1800-768
[8]
Barut V(2017)Chronic high-dose glucocorticoid therapy triggers the development of chronic organ damage and worsens disease outcome in systemic lupus erythematosus Clin Rheumatol 36 759-393
[9]
Samnaliev M(2016)Independent association of glucocorticoids with damage accrual in SLE Lupus Sci Med 3 385-393
[10]
Langham S(2020)Economic evaluation of damage accrual in an international systemic lupus erythematosus inception cohort using a multistate model approach Arthritis Care Res 72 rkab071-1013